Announcements Trials

Browse Landscape

Phase

Phase NA 3 Phase EARLY_PHASE1 1 Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1

Interventions

Cisplatin 1519 Carboplatin 1420 Cyclophosphamide 1360 Gemcitabine 1235 Bevacizumab 1226 Paclitaxel 1211 Radiotherapy 1176 Docetaxel 1080 pembrolizumab 1028 Oxaliplatin 936 Capecitabine 901 Fluorouracil 833 Rituximab 729 Doxorubicin 683 Nivolumab 679 Dexamethasone 666 Etoposide 660 Irinotecan 622 Leucovorin 575 Pemetrexed 510 Drug Therapy 493 Cetuximab 483 Trastuzumab 469 Cytarabine 466 Magnetic Resonance Spectroscopy 458 Filgrastim 446 Prednisone 433 Lenalidomide 409 Specimen Handling 408 Temozolomide 400

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carbon Monoxide × Clear all

NCT06038526 2026-05-20

Evaluation of Canakinumab in High-Risk Former-Smokers

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡